Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy

Journal of Gastroenterology

Volumn 46, Issue 3, 2011, Pages 410-414

  Lee, Hyo Suk ^a   Yoo, Byung Chul ^b   Lee, Kwan Sik ^c   Kim, Ju Hyun ^d   Um, Soon Ho ^e   Ryu, Soo Hyung ^f   Lee, Young Suk ^g   Kim, Young Soo ^h   Yoo, Kwon ⁱ   Han, Joon Yeol ^g   Hwang, Jae Seok ^j   Kim, Tae Hun ⁱ   Yang, Jin Mo ^g   Lee, Heon Ju ^k   Chon, Chae Yoon ^c   Cho, Mong ^l   Han, Byung Hoon ^m   Hwang, Seong Gyu ⁿ   Byun, Kwan Soo ^e   Chung, Young Hwa ^o   Cho, Se Hyun ^g   Koh, Kwang Cheol ^b   Kim, Byung Ik ^p   Kim, Haak Cheoul ^q   Paik, Seung Woon ^b   Lee, Myung Seok ^r   Yoo, Hee Won ^s   Han, Cheol Ju ^t   more..

^a Seoul National University Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yonsei University   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e Korea University Ansan Hospital   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Inha University Hospital   (South Korea)

ⁱ Mokdong Hospital   (South Korea)

^j Dongsan Medical Center   (South Korea)

^k Yeungnam University Hospital   (South Korea)

^l Pusan National University Hospital   (South Korea)

^m Kosin Medical School   (South Korea)

ⁿ CHA University   (South Korea)

^o Asan Medical Center   (South Korea)

^p Samsung Medical Center   (South Korea)

^q Wonkwang University Hospital   (South Korea)

^r Hallym University Medical Center   (South Korea)

^s Bukwang Pharmaceutical Company   (South Korea)

^t Korea Institute of Radiation and Medical Science   (South Korea)

more..

Author keywords

ccc DNA; HBeAg seroconversion; HBsAg loss; HBV DNA; Hepatitis B virus

Indexed keywords

ALANINE AMINOTRANSFERASE; CLEVUDINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ANTIBODY TITER; ARTICLE; ASTHENIA; DRUG RESPONSE; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA, VIRAL; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; VIRAL LOAD;

EID: 79954420265     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0354-x     Document Type: Article

References (27)

1. WM Lee 1997 Hepatitis B infection N Engl J Med 337 1733 1745 9392700 10.1056/NEJM199712113372406 1:STN:280:DyaK1c%2FktFyjtA%3D%3D (Pubitemid 27527771)
2. JL Dienstag RD Goldin EJ Heathcote HW Hann M Woessner SL Stephenson, et al. 2003 Histological outcome during long-term lamivudine therapy Gastroenterology 124 105 117 12512035 10.1053/gast.2003.50013 1:CAS:528:DC%2BD3sXot1antQ%3D%3D (Pubitemid 36055344)
3. NW Leung CL Lai TT Chang R Guan CM Lee KY Ng, et al. 2001 Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 1527 1532 11391543 10.1053/jhep.2001.25084 1:CAS:528:DC%2BD3MXktlygtLc%3D (Pubitemid 32496991)
4. R Perrilo E Schiff E Yoshida A Statler K Hirsch T Wright, et al. 2000 Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants Hepatology 32 129 134 10.1053/jhep.2000.8626 (Pubitemid 30432377)
5. TT Chang RG Gish SJ Hadziyannis J Cianciara M Rizzetto ER Schiff, et al. 2005 A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients Gastroenterology 129 1198 1209 16230074 10.1053/j.gastro.2005.06.055 1:CAS:528:DC%2BD2MXhtFyltb%2FJ (Pubitemid 41446860)
6. TT Chang RG Gish R de Man A Gadano J Sollano YC Chao, et al. 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 16525137 10.1056/NEJMoa051285 1:CAS:528: DC%2BD28XitFWms7Y%3D (Pubitemid 43357804)
7. CL Lai E Gane YF Liaw CW Hsu S Thongsawat Y Wang, et al. 2007 Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2576 2588 18094378 10.1056/NEJMoa066422 1:CAS:528:DC%2BD2sXhsVKht7nF (Pubitemid 350294224)
8. P Marcellin EJ Heathcote M Buti E Gane RA de Man Z Krastev, et al. 2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2442 2455 19052126 10.1056/NEJMoa0802878 1:CAS:528: DC%2BD1cXhsVCrurjL
9. CK Chu T Ma K Shanmuganathan C Wang Y Xiang SB Pai, et al. 1995 Use of 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus Antimicrob Agents Chemother 39 979 981 7786007 1:CAS:528:DyaK2MXkvFyit7o%3D
10. SF Peek PJ Cote JR Jacob IA Toshkov WE Hornbuckle BH Baldwin, et al. 2001 Antiviral activity of clevudine [l-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) Hepatology 33 254 266 11124844 10.1053/jhep.2001.20899 1:CAS:528:DC%2BD3MXktFajtA%3D%3D (Pubitemid 32016909)
11. CK Chu FD Boudinot SF Peek JH Hong Y Choi BE Korba, et al. 1998 Preclinical investigation of l-FMAU as an anti-hepatitis B virus agent Antivir Ther 3 suppl 3 113 121 10726061 1:CAS:528:DyaK1cXnvVOnurw%3D (Pubitemid 28528327)
12. Y Zhu T Yamamoto J Cullen J Saputelli CE Aldrich DS Miller, et al. 2001 Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis J Virol 75 311 322 11119601 10.1128/JVI.75.1.311-322.2001 1:CAS:528:DC%2BD3cXovV2jtbw%3D
13. J Summers WS Mason 2004 Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy Proc Natl Acad Sci USA 101 638 640 14699050 10.1073/pnas.0307422100 1:CAS:528:DC%2BD2cXmsFGmuw%3D%3D (Pubitemid 38084689)
14. BC Yoo JH Kim YH Chung KS Lee SW Paik SH Ryu, et al. 2007 Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 45 1172 1178 17464992 10.1002/hep.21629 1:CAS:528:DC%2BD2sXlslOju7w%3D (Pubitemid 46775779)
15. BC Yoo JH Kim TH Kim KC Koh SH Um YS Kim, et al. 2007 Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression Hepatology 46 1041 1048 17647293 10.1002/hep.21800 1:CAS:528:DC%2BD2sXht1aksr3J (Pubitemid 350144769)
16. YH Chung KS Lee JH Kim SH Ryu SW Paik SH Um, et al. 2006 One-year treatment with clevudine demonstrated significant viral suppression and biochemical improvement J Hepatol 44 S25 10.1016/S0168-8278(06)80054-1
17. KM Lee SW Cho SW Kim HJ Kim KB Hahm JH Kim 2002 Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion J Viral Hepat 9 208 212 12010509 10.1046/j.1365-2893.2002.00357.x 1:STN:280:DC%2BD383nt1artA%3D%3D (Pubitemid 36005519)
18. BC Song DJ Suh HC Lee YH Chung YS Lee 2000 Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 803 806 11003626 10.1053/jhep.2000.16665 1:CAS:528:DC%2BD3cXnslemsbg%3D
19. HL Chan VW Wong AM Tse CH Tse AM Chim HY Chan, et al. 2007 Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 1462 1468 18054753 10.1016/j.cgh.2007.09.005 1:CAS:528:DC%2BD1cXlslSqsg%3D%3D (Pubitemid 350181604)
20. S Menne CA Roneker BC Tennant BE Korba JL Gerin PJ Cote 2002 Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection Intervirology 45 237 250 12566706 10.1159/000067914 1:CAS:528:DC%2BD3sXosVOmuw%3D%3D (Pubitemid 36173432)
21. BK Kim J Oh SY Kwon WH Choe SY Ko KH Rhee, et al. 2009 Clevudine myopathy in patients with chronic hepatitis B J Hepatol 51 829 834 19615776 10.1016/j.jhep.2009.04.019
22. JI Seok DK Lee CH Lee MS Park SY Kim HS Kim, et al. 2009 Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA Hepatology 49 2080 2086 19333909 10.1002/hep.22959 1:CAS:528:DC%2BD1MXotVCmurg%3D
23. WY Tak SY Park CM Cho MK Jung SW Jeon YO Kweon, et al. 2010 Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy J Hepatol 53 261 266 20466447 10.1016/j.jhep.2010.03.006 1:CAS:528: DC%2BC3cXosVGrsb4%3D
24. Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, et al. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat. 2010 [Epub ahead of print].
25. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, et al. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat. 2010 [Epub ahead of print].
26. RD Fleischer AS Lok 2009 Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B J Hepatol 51 787 791 19665816 10.1016/j.jhep.2009.06.011 1:CAS:528:DC%2BD1MXhtFagt7%2FJ
27. YF Liaw E Gane N Leung S Zeuzem Y Wang CL Lai, et al. 2009 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 486 495 19027013 10.1053/j.gastro.2008.10.026 1:CAS:528:DC%2BD1MXislOhtLs%3D